20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Pfizer Inc (NYSE:PFE) and Merck & Co Inc (NYSE:MRK) have reportedly lowered the prices of their respective COVID-19 treatments in China.
- Pfizer cut the price of Paxlovid by about 100 yuan ($14.54) to 1,790 yuan per box of 30 pills, while Merck marginally lowered the price of a 40-capsule bottle of its oral treatment molnupiravir by 74 yuan to 1,426 yuan, Reuters reported citing the financial news outlet, Yicai.
- Earlier this year, the companies had not agreed to a request by the Chinese authorities for deeper price cuts for COVID-19 treatments.
- The marginal decline in prices follows China adjusted medical insurance coverage policy for COVID-19 treatments following the abrupt lifting of its zero-COVID policy in early December.
- Previously, under a temporary policy China enacted for COVID-19 treatments, insured patients only needed to pay 10% of the price for Paxlovid and Merck.
- That policy expired on March 31, meaning they must now pay full price.
- In January, Pfizer CEO Albert Bourla rebuffed reports saying the company is in talks with Chinese authorities to license a generic version of its Covid-19 treatment Paxlovid.
- Price Action: MRK stock is up 0.27% at $109.16, and PFE shares are up 0.24% at $41.45 during the premarket session on the last check Tuesday.
- Photo via Company
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!